Ovitrelle (Choriogonadotropin alfa)

Ovitrelle (choriogonadotropin alfa) is indicated in the treatment of

• Adult women undergoing superovulation before assisted reproductive technologies (ART), such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.
• Anovulatory or oligo-ovulatory adult women: Ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory women after stimulation of follicular growth.

Recommended Dosage:
The maximum dose of Ovitrelle is 250 micrograms. This medicine is injected subcutaneously (under the skin), usually in the abdomen. It must be administered under the supervision of a doctor experienced in fertility issues. Self-administration should only be performed by patients who are properly trained and have access to expert advice. It is for single use only. The following dose regimen of Ovitrelle (choriogonadotropin alfa) should be used:

• Women undergoing superovulation before assisted reproductive technologies (ART) such as in vitro fertilisation (IVF): One pre-filled syringe of Ovitrelle (250 micrograms) is administered 24-48 hours after the last administration of a follicle-stimulating hormone (FSH) or human menopausal gonadotropin (hMG) preparation, i.e., when optimal stimulation of follicular growth is achieved.
• Anovulatory or oligo-ovulatory women: One pre-filled syringe of Ovitrelle (250 micrograms) is administered 24-48 hours after optimal stimulation of follicular growth is achieved. The patient is recommended to have coitus on the day of, and the day after, Ovitrelle injection.

• This medicine may overstimulate the ovaries, causing them to produce excess follicles and large fluid-filled cysts. This condition can become severe. Symptoms include nausea, vomiting, severe abdominal pain, rapid weight gain, diarrhea, bloating, and difficulty breathing. Ask for immediate medical attention if these occur.
• Treatment with gonadotropins such as Ovitrelle may increase the probability of blood clots forming in the veins or lungs. The risk is higher in women with obesity, smoking habits, or personal or family history of clotting disorders. Prompt medical care is recommended.
• Use of this injection increases the chance of multiple pregnancies, including twins or higher-order multiples. Multiple pregnancies carry greater health complications for both mother and babies, such as premature birth, low birth weight, and pregnancy-related complications requiring proper medical monitoring.
• Women with a history of fallopian tube complications have an increased risk of ectopic pregnancy when using fertility treatments like Ovitrelle. An ectopic pregnancy occurs outside the uterus and can be dangerous. Early ultrasound examination is recommended to confirm the normal pregnancy location.
• Because this drug contains human chorionic gonadotropin (hCG), it may cause false-positive pregnancy test results. Blood or urine pregnancy tests can remain positive for up to ten days after injection. Testing should be done only as advised by your healthcare provider.
• There have been data on benign and malignant tumors of the ovaries and reproductive organs in women undergoing repeated fertility treatments. While a direct link is unclear, regular medical monitoring and discussion of risks are important before multiple treatment cycles.
• Do not use this medicine if you are allergic to choriogonadotropin alfa or any ingredient in the formulation. Signs of allergic reaction may include itching, rash, swelling, dizziness, or breathing difficulty. Ask for immediate medical attention if hypersensitivity occurs.
• Ovitrelle should not be used in women with tumors of the hypothalamus, pituitary gland, breast, uterus, or ovaries. Hormonal stimulation may worsen certain hormone-sensitive cancers. A full medical evaluation is required before starting treatment.
• Do not use this medicinal product if you have ovarian enlargement or ovarian cysts that are not caused by polycystic ovarian syndrome. Fertility stimulation can worsen these conditions and increase the risk of serious complications such as ovarian torsion, rupture, or internal bleeding.
• Ovitrelle must not be used if you experience abnormal vaginal bleeding without a confirmed medical cause. A complete evaluation by a doctor is necessary before starting treatment. Using fertility medication without identifying the reason for bleeding may delay diagnosis of serious conditions.
• Women diagnosed with primary ovarian failure, including natural menopause, should not use Ovitrelle. In this condition, the ovaries do not respond to hormonal stimulation. Treatment would not be effective and may unnecessarily expose the patient to hormonal side effects and health risks.
• Ovitrelle should not be used in patients who have active or severe blood-clotting disorders. Hormonal stimulation may increase the risk of forming blood clots and worsen existing conditions. This can potentially lead to serious or life-threatening complications requiring urgent medical care.
• After preparing the Ovitrelle solution, it should be used immediately as instructed. Delayed use may reduce sterility and effectiveness. Do not store the mixed solution for future use. Always follow the preparation and administration instructions provided by your healthcare professional carefully.
• Ovitrelle must not be used if you are already pregnant or currently breastfeeding. It is designed to trigger ovulation before conception. If pregnancy occurs during treatment, inform your doctor immediately to ensure appropriate medical guidance and safety monitoring.
• Tell your doctor about all medicines you are taking, including prescription drugs, over-the-counter products, and herbal supplements. Although major interactions are uncommon, medical supervision is important to ensure safe fertility treatment and avoid unexpected side effects or reduced effectiveness.

What documents are required to import OVITRELLE to India?

OVITRELLE (choriogonadotropin alfa) injections can be imported by patients or government hospitals in the name of the patients only.

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?
The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is OVITRELLE available in India?

OVITRELLE (choriogonadotropin alfa injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Ovitrelle in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Ovitrelle price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

OVITRELLE can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of OVITRELLE (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91 98104 69557 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Ovitrelle cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source OVITRELLE (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Ovitrelle®?

Choriogonadotropin alfa is the Generic Name for the trade name drug Ovitrelle®.

What is the Manufacturer’s Name of Ovitrelle®?

Ovitrelle® is manufactured by Merck Group.

Is Ovitrelle the same as Ovidrel in the U.S.?

Yes, Ovitrelle and Ovidrel contain the same active ingredient, recombinant human chorionic gonadotropin (r-hCG). The only difference is the brand name used in different regions. Ovitrelle is marketed in Europe and several other countries, while Ovidrel is the brand name available in the United States. Both medicines work in the same way and have the same therapeutic purpose.

Is Ovitrelle approved by the FDA?

Ovitrelle, known as Ovidrel (choriogonadotropin alfa) in the United States, was approved by the FDA for the 250 micrograms/0.5 mL dosage on September 20, 2000.

What is the dosage and form of Ovitrelle® supplied?

Ovitrelle is supplied as an injection: 250 micrograms choriogonadotropin alfa (equivalent to approximately 6,500 IU) in 0.5 mL solution for subcutaneous use.

What are the most common side effects of Ovitrelle® 250 micrograms/0.5 mL Injections?

The most commonly reported side effects of Ovitrelle® are headache, fatigue, local reactions in the injection area, swelling or abdominal pain, gastrointestinal disorders (such as diarrhea or nausea), breast pain, and mild or moderate ovarian hyperstimulation syndrome (OHSS).

Does menstruation start earlier with Ovitrelle?

Ovitrelle triggers final egg maturation and ovulation but does not usually cause earlier menstruation. Your period typically begins about two weeks after ovulation if pregnancy does not occur. If conception happens, menstruation will not start, as pregnancy prevents the menstrual cycle.

How does Ovitrelle Import in India work?

Ovitrelle Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

How much does Ovitrelle® 250 micrograms/0.5 mL injection cost in India?

Ovitrelle® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Ovitrelle prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Ovitrelle cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Ovitrelle® 250 micrograms/0.5 mL injection be available in SAARC countries?

Apart from Gulf countries, Ovitrelle® 250 micrograms/0.5 mL can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Ovitrelle® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Ovitrelle® 250 micrograms/0.5 mL Injections online in India?

Yes, one can buy Ovitrelle in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Ovitrelle® injection through legal channels.

What are the storage conditions of Ovitrelle® 250 micrograms/0.5 mL Injections?

Store in a refrigerator (2°C – 8°C). If not refrigerated, it can be stored at room temperature (below 25°C) for up to 30 days, but must be discarded if not used within that time.